Department of Neurosurgery, University of Rouen, Rouen, France.
Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, 80 Avenue Augustin Fliche, Montpellier, 34295, France.
Acta Neurochir (Wien). 2024 Oct 28;166(1):425. doi: 10.1007/s00701-024-06321-6.
Second and third surgeries were demonstrated as safe and efficient in recurrent diffuse low-grade glioma (LGG). Here, the feasibility of more than 3 resections is investigated.
Patients who underwent 4 or 5 operations for recurrent initially WHO grade 2 IDH-mutated gliomas were consecutively selected.
Twenty-three operations were performed in five patients (all males, mean age 27.2 ± 4 years). Three patients underwent 5 surgeries and two patients underwent 4 surgeries. Twelve procedures (52%) were achieved with awake mapping, including all 4th and 5th operations but one. Repeat electrical mapping detected changes of the cortical maps between at least two awake surgeries in 4 patients. No patients experienced permanent neurological impairment (KPS score ≥ 80 in all cases). The patients returned to work after 22 surgeries among 23 (95.6%). There were 3 oligodendrogliomas and 2 astrocytomas (4 gliomas became malignant at fourth or fifth operation). Although the preoperative tumor volume significantly increased before the fourth (p = 0.026) and fifth operation (p = 0.003) compared with the first operation, there was no significant difference between the residual tumor volume after the fourth or fifth resection versus the first one. The mean delay was 10.6 ± 3.9 years before chemotherapy and 15.4 ± 3.4 years before radiotherapy (one patient never received adjuvant treatment after 21.5 years). The mean follow-up duration was 18.3 ± 3.1 years since the first surgery (2.3 ± 1.8 years since the last surgery). Three patients were still alive at last follow-up.
This is the first series showing that to reoperate beyond three times is feasible with a low functional risk and a long survival in multiple LGG recurrences, with the use of awake mapping in 87.5% of 4th and 5th surgeries.
二次和三次手术已被证明在复发性弥漫性低级别胶质瘤(LGG)中是安全有效的。在此,我们研究了超过 3 次切除的可行性。
连续选择因复发性初始世界卫生组织(WHO)分级 2 型伴 IDH 突变型胶质瘤而接受 4 或 5 次手术的患者。
5 名患者(均为男性,平均年龄 27.2±4 岁)共进行了 23 次手术。其中 3 名患者进行了 5 次手术,2 名患者进行了 4 次手术。12 次手术(52%)采用了清醒脑功能区定位,包括所有第 4 次和第 5 次手术,但有一次除外。4 名患者的重复电刺激脑功能区定位检测到至少两次清醒手术之间皮质映射图的变化。所有患者(KPS 评分均≥80)均未出现永久性神经功能障碍。23 次手术中有 22 次(95.6%)患者术后恢复工作。其中 3 例为少突胶质细胞瘤,2 例为星形细胞瘤(4 例胶质瘤在第 4 或第 5 次手术时发生恶变)。尽管与首次手术相比,第四次(p=0.026)和第五次(p=0.003)手术前的术前肿瘤体积明显增加,但第四次或第五次切除后与首次切除的残余肿瘤体积无显著差异。在化疗前的平均延迟时间为 10.6±3.9 年,在放疗前的平均延迟时间为 15.4±3.4 年(1 例患者在 21.5 年后从未接受过辅助治疗)。自首次手术以来的平均随访时间为 18.3±3.1 年(末次手术以来的随访时间为 2.3±1.8 年)。截至最后随访时,有 3 例患者仍然存活。
这是首次系列研究表明,在多次 LGG 复发中,在功能风险较低的情况下,进行 3 次以上的手术是可行的,并且在 87.5%的第 4 次和第 5 次手术中使用了清醒脑功能区定位。